IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
Metastatic tumour recurrence due to failed treatments remains a major challenge of breast cancer clinical management. Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer (TNBC), where it acts to drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment. We show that IRAK1 overexpression confers TNBC growth advantage through NF-kappaB-related cytokine secretion and metastatic TNBC cells exhibit gain of IRAK1 dependency, resulting in high susceptibility to genetic and pharmacologic inhibition of IRAK1. Importantly, paclitaxel treatment induces strong IRAK1 phosphorylation, an increase in inflammatory cytokine expression, enrichment of cancer stem cells and acquired resistance to paclitaxel treatment. Pharmacologic inhibition of IRAK1 is able to reverse paclitaxel resistance by triggering massive apoptosis at least in part through inhibiting p38-MCL1 pro-survival pathway. Our study thus demonstrates IRAK1 as a promising therapeutic target for TNBC metastasis and paclitaxel resistance.
|ISBN||2041-1723 (Electronic) 2041-1723 (Linking)|
|Authors||Wee, Z. N.; Yatim, S. M.; Kohlbauer, V. K.; Feng, M.; Goh, J. Y.; Yi, B.; Lee, P. L.; Zhang, S.; Wang, P. P.; Lim, E.; Tam, W. L.; Cai, Y.; Ditzel, H. J.; Hoon, D. S.; Tan, E. Y.; Yu, Q.;|
|Publisher Name||Nature Communications|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/26503059|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/13095|